"The Global Minimal Residual Disease Testing Market was valued at USD 2.18 billion in 2025 and is projected to reach USD 8.36 billion by 2034, growing at a CAGR of 16.13%."
The Minimal Residual Disease (MRD) Testing Market is witnessing significant growth as precision oncology and hematological cancer monitoring continue to advance. MRD testing enables the detection of trace amounts of cancer cells that remain in a patient’s body after treatment, which may not be visible through conventional imaging or morphological tests. The growing integration of next-generation sequencing (NGS), flow cytometry, and polymerase chain reaction (PCR) technologies has revolutionized MRD detection by offering highly sensitive, specific, and quantitative insights. This capability plays a pivotal role in guiding treatment decisions, assessing relapse risk, and personalizing patient management in leukemia, lymphoma, multiple myeloma, and other hematologic malignancies. As clinical evidence for MRD’s predictive and prognostic value increases, healthcare systems and providers are incorporating MRD as a standard element of cancer care pathways.
Pharmaceutical companies are also leveraging MRD status as a surrogate endpoint in clinical trials to accelerate drug development timelines. Additionally, payers are gradually recognizing the cost-effectiveness of MRD monitoring by helping prevent overtreatment and avoid relapse. Market growth is further driven by the expansion of clinical guidelines, rising cancer incidence, and increased R&D investments in MRD assays. Strategic partnerships between diagnostics firms, biotech companies, and healthcare institutions are enhancing market penetration and technology adoption. Despite reimbursement hurdles and technical complexity, the MRD testing market is rapidly evolving, with diagnostic innovation and clinical integration setting the foundation for long-term expansion across global oncology care networks.
North America – Minimal Residual Disease Testing MarketNorth America leads the minimal residual disease (MRD) testing market due to its mature healthcare infrastructure, early adoption of advanced diagnostic platforms, and high prevalence of hematological malignancies. The presence of major biotechnology companies and academic institutions fosters continuous innovation in MRD testing technologies such as next-generation sequencing (NGS), real-time PCR, and flow cytometry. Integration of MRD into clinical protocols for leukemia and lymphoma has grown significantly, especially within cancer care centers and transplant programs. Reimbursement support for MRD assays and regulatory recognition of MRD as a prognostic marker are also reinforcing its routine clinical use across the U.S. and Canada.
Asia Pacific – Minimal Residual Disease Testing MarketThe Asia Pacific region is witnessing robust growth in the MRD testing market, supported by rising cancer incidences, healthcare infrastructure development, and increasing demand for personalized treatment approaches. Countries like China, Japan, and India are heavily investing in diagnostic upgrades and clinical trials, expanding MRD accessibility across public and private hospitals. The market is also benefiting from the localization of MRD assay manufacturing and tailored diagnostic solutions to meet regional cost constraints. Government-backed cancer screening programs and partnerships with global diagnostic firms are contributing to a steady uptake of MRD tests in both urban and tier-2 cities across Asia Pacific.
Europe – Minimal Residual Disease Testing MarketEurope maintains a strong presence in the MRD testing market, driven by clinical guidelines mandating MRD monitoring in multiple myeloma and acute lymphoblastic leukemia treatments. Countries like Germany, the UK, France, and the Netherlands are at the forefront of MRD adoption, supported by centralized healthcare systems and evidence-based policymaking. Ongoing collaborative research projects, along with regulatory frameworks that promote diagnostic standardization, have streamlined the clinical validation of MRD assays. The expansion of molecular diagnostics labs and integration of MRD testing in post-transplant monitoring continue to offer new commercial opportunities for MRD technology providers across Europe.
Key Insights
- The growing clinical acceptance of MRD testing is transforming how hematologic malignancies such as leukemia, lymphoma, and multiple myeloma are monitored post-treatment, with oncologists relying on MRD results for therapy adjustments and relapse risk assessment.
- Next-generation sequencing (NGS) based MRD assays are gaining widespread adoption due to their ultra-sensitive detection thresholds, enabling clinicians to identify one cancer cell among a million normal cells, improving precision in treatment planning.
- Flow cytometry continues to dominate in hospital and academic settings for its speed and affordability, though its sensitivity is lower compared to NGS, leading to a dual-technology approach in many oncology programs globally.
- MRD testing is increasingly being used as a surrogate endpoint in clinical trials, helping biopharmaceutical companies accelerate approval timelines for novel oncology drugs and reducing long-term study costs.
- Collaborations between diagnostics firms and cancer research centers are fueling innovation in assay development, including multiplex platforms that can simultaneously track multiple cancer biomarkers through a single sample.
- North America leads in MRD test adoption due to a well-established healthcare infrastructure, strong R&D investment, and supportive oncology guidelines, while Asia Pacific is witnessing the fastest growth fueled by rising cancer prevalence and access to advanced diagnostics.
- Regulatory approvals of commercial MRD kits, especially from players in the US and Europe, are improving access and driving integration of MRD into standard cancer care pathways beyond academic institutions.
- Payers are beginning to reimburse MRD testing in select regions as real-world evidence demonstrates cost savings through reduced relapse rates and optimized therapy durations, particularly in chronic lymphocytic leukemia and myeloma cases.
- Digital health tools and AI-based analytics are being integrated into MRD platforms to enable real-time monitoring, interpretation of large genomic datasets, and improved clinical decision-making workflows for personalized cancer care.
- Technical challenges such as standardization, assay validation, and interpretation consistency remain industry-wide hurdles, prompting regulatory agencies and professional societies to work on harmonized MRD testing protocols globally.
Market Scope
| Parameter | Detail |
|---|---|
| Base Year | 2024 |
| Estimated Year | 2025 |
| Forecast Period | 2026-2034 |
| Market Size-Units | USD billion |
| Market Splits Covered | By Product Type , By Application , By End User , By Technology , By Distribution Channel |
| Countries Covered | North America (USA, Canada, Mexico) Europe (Germany, UK, France, Spain, Italy, Rest of Europe) Asia-Pacific (China, India, Japan, Australia, Rest of APAC) The Middle East and Africa (Middle East, Africa) South and Central America (Brazil, Argentina, Rest of SCA) |
| Analysis Covered | Latest Trends, Driving Factors, Challenges, Supply-Chain Analysis, Competitive Landscape, Company Strategies |
| Customization | 10 % free customization (up to 10 analyst hours) to modify segments, geographies, and companies analyzed |
| Post-Sale Support | 4 analyst hours, available up to 4 weeks |
| Delivery Format | The Latest Updated PDF and Excel Datafile |
Minimal Residual Disease Testing Market Segmentation
By Product Type
- PCR Based Tests
- NGS Based Tests
By Application
- Hematological Malignancies
- Solid Tumors
By End User
- Hospitals
- Laboratories
By Technology
- Molecular Diagnostics
- Flow Cytometry
By Distribution Channel
- Direct Sales
- Distributor Sales
By Geography
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Spain, Italy, Rest of Europe)
- Asia-Pacific (China, India, Japan, Australia, Vietnam, Rest of APAC)
- The Middle East and Africa (Middle East, Africa)
- South and Central America (Brazil, Argentina, Rest of SCA)
Key Companies Covered
F. Hoffmann‑La Roche Ltd, Labcorp Inc., Guardant Health, Sysmex Corporation, NeoGenomics Laboratories Inc., Adaptive Biotechnologies Corporation, ArcherDX Inc., Asuragen Inc., ARUP Laboratories Inc., Bio‑Rad Laboratories Inc., Exact Sciences Corporation, GRAIL LLC, Veracyte Inc., Natera Inc., QIAGEN N.V., FOUNDATION MEDICINE Inc., Invivoscribe Inc., Bristol‑Myers Squibb Company, Amgen Inc., Cergentis B.V., Quest Diagnostics, Inivita, mdxhealth, Personalis (NeXT Personal assay), ICON plc, Bio‑Techne.Recent Developments
- July 2025 – Adaptive Biotechnologies
Adaptive Biotechnologies partnered with Flatiron Health to integrate its clonoSEQ® MRD test into the OncoEMR® oncology electronic medical record platform, facilitating streamlined access to MRD data for clinicians. - June 2025 – Natera
Natera launched its ultra‑sensitive Signatera™ Genome MRD test for broad clinical use in the U.S., validated across thousands of plasma samples and set to be featured at the 2025 ASCO Annual Meeting. - June 2025 – Guardant Health
A new study published in ESMO Open demonstrated that Guardant Reveal’s breast cancer ctDNA detection had 100% sensitivity and specificity in predicting distant recurrence, with a median lead time of several months ahead of imaging. - May 2025 – Foresight Diagnostics & QIAGEN
QIAGEN announced collaborations with Foresight Diagnostics and Tracer Biotechnologies to commercialize kit-based versions of CLARITY™ and PCR-based MRD assays, enabling decentralized testing in hematological and solid tumors. - May 2025 – Foresight Diagnostics
Foresight presented ASCO 2025 data showing that its CLARITY™ ctDNA-MRD platform—powered by PhasED‑Seq™—can identify patients at higher relapse risk in diffuse large B‑cell lymphoma with high sensitivity. - May/June 2025 – Telo Genomics
Telo Genomics had its TeloView® multiple myeloma MRD methodology accepted for publication at ASCO 2025, highlighting its liquid biopsy approach for quantifying and profiling residual disease post-transplant. - June 2025 – Telo Genomics
Telo Genomics initiated a clinical trial for its MM‑MRD assay in collaboration with the Cleveland Clinic Cancer Institute, aiming to stratify multiple myeloma patients by MRD burden and cell aggressiveness. - June 2025 – Myriad Genetics
Myriad shared new ASCO data validating its Precise® MRD test across multiple cancer types, and formalized a strategic alliance with MD Anderson to assess clinical utility in collaborative trials.
What You Receive
• Global Minimal Residual Disease Testing market size and growth projections (CAGR), 2024- 2034• Impact of recent changes in geopolitical, economic, and trade policies on the demand and supply chain of Minimal Residual Disease Testing.
• Minimal Residual Disease Testing market size, share, and outlook across 5 regions and 27 countries, 2025- 2034.
• Minimal Residual Disease Testing market size, CAGR, and Market Share of key products, applications, and end-user verticals, 2025- 2034.
• Short and long-term Minimal Residual Disease Testing market trends, drivers, restraints, and opportunities.
• Porter’s Five Forces analysis, Technological developments in the Minimal Residual Disease Testing market, Minimal Residual Disease Testing supply chain analysis.
• Minimal Residual Disease Testing trade analysis, Minimal Residual Disease Testing market price analysis, Minimal Residual Disease Testing Value Chain Analysis.
• Profiles of 5 leading companies in the industry- overview, key strategies, financials, and products.
• Latest Minimal Residual Disease Testing market news and developments.
The Minimal Residual Disease Testing Market international scenario is well established in the report with separate chapters on North America Minimal Residual Disease Testing Market, Europe Minimal Residual Disease Testing Market, Asia-Pacific Minimal Residual Disease Testing Market, Middle East and Africa Minimal Residual Disease Testing Market, and South and Central America Minimal Residual Disease Testing Markets. These sections further fragment the regional Minimal Residual Disease Testing market by type, application, end-user, and country.
1.1 List of Tables
1.2 List of Figures
2. Minimal Residual Disease Testing Market Latest Trends, Drivers and Challenges, 2024- 2034
2.1 Minimal Residual Disease Testing Market Overview
2.2 Market Strategies of Leading Minimal Residual Disease Testing Companies
2.3 Minimal Residual Disease Testing Market Insights, 2024- 2034
2.3.1 Leading Minimal Residual Disease Testing Types, 2024- 2034
2.3.2 Leading Minimal Residual Disease Testing End-User industries, 2024- 2034
2.3.3 Fast-Growing countries for Minimal Residual Disease Testing sales, 2024- 2034
2.4 Minimal Residual Disease Testing Market Drivers and Restraints
2.4.1 Minimal Residual Disease Testing Demand Drivers to 2034
2.4.2 Minimal Residual Disease Testing Challenges to 2034
2.5 Minimal Residual Disease Testing Market- Five Forces Analysis
2.5.1 Minimal Residual Disease Testing Industry Attractiveness Index, 2024
2.5.2 Threat of New Entrants
2.5.3 Bargaining Power of Suppliers
2.5.4 Bargaining Power of Buyers
2.5.5 Intensity of Competitive Rivalry
2.5.6 Threat of Substitutes
3. Global Minimal Residual Disease Testing Market Value, Market Share, and Forecast to 2034
3.1 Global Minimal Residual Disease Testing Market Overview, 2024
3.2 Global Minimal Residual Disease Testing Market Revenue and Forecast, 2024- 2034 (US$ billion)
3.3 Global Minimal Residual Disease Testing Market Size and Share Outlook By Product, 2024- 2034
3.4 Global Minimal Residual Disease Testing Market Size and Share Outlook By Application, 2024- 2034
3.5 Global Minimal Residual Disease Testing Market Size and Share Outlook By End User, 2024- 2034
3.6 Global Minimal Residual Disease Testing Market Size and Share Outlook By Technology, 2024- 2034
3.7 Global Minimal Residual Disease Testing Market Size and Share Outlook by Region, 2024- 2034
4. Asia Pacific Minimal Residual Disease Testing Market Value, Market Share and Forecast to 2034
4.1 Asia Pacific Minimal Residual Disease Testing Market Overview, 2024
4.2 Asia Pacific Minimal Residual Disease Testing Market Revenue and Forecast, 2024- 2034 (US$ billion)
4.3 Asia Pacific Minimal Residual Disease Testing Market Size and Share Outlook By Product, 2024- 2034
4.4 Asia Pacific Minimal Residual Disease Testing Market Size and Share Outlook By Application, 2024- 2034
4.5 Asia Pacific Minimal Residual Disease Testing Market Size and Share Outlook By End User, 2024- 2034
4.6 Asia Pacific Minimal Residual Disease Testing Market Size and Share Outlook By Technology, 2024- 2034
4.7 Asia Pacific Minimal Residual Disease Testing Market Size and Share Outlook by Country, 2024- 2034
5. Europe Minimal Residual Disease Testing Market Value, Market Share, and Forecast to 2034
5.1 Europe Minimal Residual Disease Testing Market Overview, 2024
5.2 Europe Minimal Residual Disease Testing Market Revenue and Forecast, 2024- 2034 (US$ billion)
5.3 Europe Minimal Residual Disease Testing Market Size and Share Outlook By Product, 2024- 2034
5.4 Europe Minimal Residual Disease Testing Market Size and Share Outlook By Application, 2024- 2034
5.5 Europe Minimal Residual Disease Testing Market Size and Share Outlook By End User, 2024- 2034
5.6 Europe Minimal Residual Disease Testing Market Size and Share Outlook By Technology, 2024- 2034
5.7 Europe Minimal Residual Disease Testing Market Size and Share Outlook by Country, 2024- 2034
6. North America Minimal Residual Disease Testing Market Value, Market Share and Forecast to 2034
6.1 North America Minimal Residual Disease Testing Market Overview, 2024
6.2 North America Minimal Residual Disease Testing Market Revenue and Forecast, 2024- 2034 (US$ billion)
6.3 North America Minimal Residual Disease Testing Market Size and Share Outlook By Product, 2024- 2034
6.4 North America Minimal Residual Disease Testing Market Size and Share Outlook By Application, 2024- 2034
6.5 North America Minimal Residual Disease Testing Market Size and Share Outlook By End User, 2024- 2034
6.6 North America Minimal Residual Disease Testing Market Size and Share Outlook By Technology, 2024- 2034
6.7 North America Minimal Residual Disease Testing Market Size and Share Outlook by Country, 2024- 2034
7. South and Central America Minimal Residual Disease Testing Market Value, Market Share and Forecast to 2034
7.1 South and Central America Minimal Residual Disease Testing Market Overview, 2024
7.2 South and Central America Minimal Residual Disease Testing Market Revenue and Forecast, 2024- 2034 (US$ billion)
7.3 South and Central America Minimal Residual Disease Testing Market Size and Share Outlook By Product, 2024- 2034
7.4 South and Central America Minimal Residual Disease Testing Market Size and Share Outlook By Application, 2024- 2034
7.5 South and Central America Minimal Residual Disease Testing Market Size and Share Outlook By End User, 2024- 2034
7.6 South and Central America Minimal Residual Disease Testing Market Size and Share Outlook By Technology, 2024- 2034
7.7 South and Central America Minimal Residual Disease Testing Market Size and Share Outlook by Country, 2024- 2034
8. Middle East Africa Minimal Residual Disease Testing Market Value, Market Share and Forecast to 2034
8.1 Middle East Africa Minimal Residual Disease Testing Market Overview, 2024
8.2 Middle East and Africa Minimal Residual Disease Testing Market Revenue and Forecast, 2024- 2034 (US$ billion)
8.3 Middle East Africa Minimal Residual Disease Testing Market Size and Share Outlook By Product, 2024- 2034
8.4 Middle East Africa Minimal Residual Disease Testing Market Size and Share Outlook By Application, 2024- 2034
8.5 Middle East Africa Minimal Residual Disease Testing Market Size and Share Outlook By End User, 2024- 2034
8.6 Middle East Africa Minimal Residual Disease Testing Market Size and Share Outlook By Technology, 2024- 2034
8.7 Middle East Africa Minimal Residual Disease Testing Market Size and Share Outlook by Country, 2024- 2034
9. Minimal Residual Disease Testing Market Structure
9.1 Key Players
9.2 Minimal Residual Disease Testing Companies - Key Strategies and Financial Analysis
9.2.1 Snapshot
9.2.3 Business Description
9.2.4 Products and Services
9.2.5 Financial Analysis
10. Minimal Residual Disease Testing Industry Recent Developments
11 Appendix
11.1 Publisher Expertise
11.2 Research Methodology
11.3 Annual Subscription Plans
11.4 Contact Information
Get Free Sample
At OG Analysis, we understand the importance of informed decision-making in today's dynamic business landscape. To help you experience the depth and quality of our market research reports, we offer complimentary samples tailored to your specific needs.
Start Now! Please fill the form below for your free sample.
Why Request a Free Sample?
Evaluate Our Expertise: Our reports are crafted by industry experts and seasoned analysts. Requesting a sample allows you to assess the depth of research and the caliber of insights we provide.
Tailored to Your Needs: Let us know your industry, market segment, or specific topic of interest. Our free samples are customized to ensure relevance to your business objectives.
Witness Actionable Insights: See firsthand how our reports go beyond data, offering actionable insights and strategic recommendations that can drive your business forward.
Embark on your journey towards strategic decision-making by requesting a free sample from OG Analysis. Experience the caliber of insights that can transform the way you approach your business challenges.
FAQ's
The Global Minimal Residual Disease Testing Market is estimated to generate USD 2.18 billion in revenue in 2025.
The Global Minimal Residual Disease Testing Market is expected to grow at a Compound Annual Growth Rate (CAGR) of 16.13% during the forecast period from 2025 to 2034.
The Minimal Residual Disease Testing Market is estimated to reach USD 8.36 billion by 2034.
Didn’t find what you’re looking for? TALK TO OUR ANALYST TEAM
Need something within your budget? NO WORRIES! WE GOT YOU COVERED!
